A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

被引：55

作者：

Hoffman, MA

Blessing, JA

Lentz, SS

机构：

[1] Long Isl Jewish Med Ctr, Sect Hematol, Div Hematol Oncol, New Hyde Pk, NY 11040 USA

[2] Roswell Pk Canc Inst, Gynecol Oncol Grp, Stat & Data CTr, Buffalo, NY 14263 USA

[3] Wake Forest Univ, Sch Med, Gynecol Oncol Sect, Winston Salem, NC 27157 USA

来源：

GYNECOLOGIC ONCOLOGY | 2003年 / 89卷 / 01期

关键词：

D O I：

10.1016/S0090-8258(03)00007-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives. To estimate the antitumor efficacy of dolastatin-10 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of dolastatin-10 in these patients. Methods. Patients received dolastatim-10 400 mug/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles. Results. Of 28 patients evaluable for response, there were no complete or partial responses. Seven patients had stable disease and 21 patients had increasing disease. Conclusions. Dolastatin-10 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested. (C) 2003 Elsevier Science (USA). All rights reserved.

引用

页码：95 / 98

页数：4

共 19 条

[1]

AGUAYO A, 2000, P AN M AM SOC CLIN, V19, pA288

[2]

Horti Jozsef, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P552

[3] Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification [J].